478 related articles for article (PubMed ID: 19815913)
1. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease.
Heystek M; Ross JD;
Int J STD AIDS; 2009 Oct; 20(10):690-5. PubMed ID: 19815913
[TBL] [Abstract][Full Text] [Related]
2. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial.
Ross JD; Cronjé HS; Paszkowski T; Rakoczi I; Vildaite D; Kureishi A; Alefelder M; Arvis P; Reimnitz P;
Sex Transm Infect; 2006 Dec; 82(6):446-51. PubMed ID: 16723364
[TBL] [Abstract][Full Text] [Related]
3. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections.
Solomkin J; Zhao YP; Ma EL; Chen MJ; Hampel B;
Int J Antimicrob Agents; 2009 Nov; 34(5):439-45. PubMed ID: 19692210
[TBL] [Abstract][Full Text] [Related]
4. A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease.
Boothby M; Page J; Pryor R; Ross JD
Int J STD AIDS; 2010 Mar; 21(3):195-7. PubMed ID: 20215625
[TBL] [Abstract][Full Text] [Related]
5. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
6. A comparison of ciprofloxacin with doxycycline plus metronidazole in the treatment of acute pelvic inflammatory disease.
Heinonen PK; Teisala K; Miettinen A; Aine R; Punnonen R; Grönroos P
Scand J Infect Dis Suppl; 1989; 60():66-73. PubMed ID: 2756353
[TBL] [Abstract][Full Text] [Related]
7. Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial.
Aşicioğlu O; Gungorduk K; Ozdemir A; Ertas IE; Yildirim G; Sanci M; Ark C
Eur J Obstet Gynecol Reprod Biol; 2013 Nov; 171(1):116-21. PubMed ID: 23993130
[TBL] [Abstract][Full Text] [Related]
8. [Ciprofloxacin/metronidazole vs. cefoxitin/doxycycline: comparison of two therapy schedules for treatment of acute pelvic infection].
Fischbach F; Deckardt R; Graeff H
Geburtshilfe Frauenheilkd; 1994 Jun; 54(6):337-40. PubMed ID: 8088489
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study.
Judlin P; Liao Q; Liu Z; Reimnitz P; Hampel B; Arvis P
BJOG; 2010 Nov; 117(12):1475-84. PubMed ID: 20716255
[TBL] [Abstract][Full Text] [Related]
10. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.
DeAbate CA; Mathew CP; Warner JH; Heyd A; Church D
Respir Med; 2000 Nov; 94(11):1029-37. PubMed ID: 11127487
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults.
Klossek JM; Siegert R; Nikolaidis P; Arvis P; Leberre MA;
J Laryngol Otol; 2003 Jan; 117(1):43-51. PubMed ID: 12590855
[TBL] [Abstract][Full Text] [Related]
12. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV.
Kern WV; Marchetti O; Drgona L; Akan H; Aoun M; Akova M; de Bock R; Paesmans M; Viscoli C; Calandra T
J Clin Oncol; 2013 Mar; 31(9):1149-56. PubMed ID: 23358983
[TBL] [Abstract][Full Text] [Related]
13. Rufloxacin once daily versus ciprofloxacin twice daily in the treatment of patients with acute uncomplicated pyelonephritis.
Bach D; van den Berg-Segers A; Hübner A; van Breukelen G; Cesana M; Plétan Y
J Urol; 1995 Jul; 154(1):19-24. PubMed ID: 7776420
[TBL] [Abstract][Full Text] [Related]
14. Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials.
Haggerty CL; Ness RB
Clin Infect Dis; 2007 Apr; 44(7):953-60. PubMed ID: 17342647
[TBL] [Abstract][Full Text] [Related]
15. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea.
Fowler JF
J Drugs Dermatol; 2007 Jun; 6(6):641-5. PubMed ID: 17668530
[TBL] [Abstract][Full Text] [Related]
16. Moxifloxacin: new indication. Do not use in gynaecological infections or other conditions.
Prescrire Int; 2009 Oct; 18(103):207. PubMed ID: 19882788
[TBL] [Abstract][Full Text] [Related]
17. Short-course ciprofloxacin treatment of acute uncomplicated urinary tract infection in women. The minimum effective dose. The Urinary Tract Infection Study Group [corrected].
Iravani A; Tice AD; McCarty J; Sikes DH; Nolen T; Gallis HA; Whalen EP; Tosiello RL; Heyd A; Kowalsky SF
Arch Intern Med; 1995 Mar; 155(5):485-94. PubMed ID: 7864704
[TBL] [Abstract][Full Text] [Related]
18. Improvement in the clinical cure rate of outpatient management of pelvic inflammatory disease following a change in therapy.
Piyadigamage A; Wilson J
Sex Transm Infect; 2005 Jun; 81(3):233-5. PubMed ID: 15923292
[TBL] [Abstract][Full Text] [Related]
19. Moxifloxacin five-day therapy versus placebo in acute bacterial rhinosinusitis.
Hadley JA; Mösges R; Desrosiers M; Haverstock D; van Veenhuyzen D; Herman-Gnjidic Z
Laryngoscope; 2010 May; 120(5):1057-62. PubMed ID: 20422704
[TBL] [Abstract][Full Text] [Related]
20. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
